

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED**  
**大健康國際集團控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2211)**

**PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, it is expected that the Group would record a loss of not less than RMB670.0 million (equivalent to approximately HK\$805.2 million) for 2020/21.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

This announcement is made by Universal Health International Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) considers that it is expected that the Group would record a loss of not less than RMB670.0 million (equivalent to approximately HK\$805.2 million\*) for the year ended 30 June 2021 (“**2020/21**”), it was mainly attributable to the following factors:

- (i) the Group has made an analysis on the impact of the macro and industrial economic environment and performed an impairment assessment on investment in an associate and non-current assets. Attributable to the unfavourable actual performance of an associate, it is expected that an impairment provision of RMB210.0 million (equivalent to approximately HK\$252.4 million) will be made for investment in an associate. Besides, it is also expected that an impairment provision of RMB8.0 million (equivalent to approximately HK\$9.6 million) will be made for non-current assets (including intangible assets, property, plant and equipment and right-of-use assets); and
- (ii) decrease in revenue mainly resulting from the volatile novel coronavirus disease 2019 (COVID-19) pandemic (the “**Pandemic**”) and increasing competition in the north-eastern region of China. The Pandemic resulted prolonged strict control over the activities in the region, which includes travel restriction.

Despite the expected significant increase in loss for 2020/21 as compared to 2019/20, the Group strives to strengthen its marketing and promotion efforts and cost control measures to mitigate the adverse effects of the external environment.

Since the unaudited final results of the Group for 2020/21 have not yet been finalized and have not been reviewed by the audit committee of the Company, the information contained in this announcement is only based on the current available information and the preliminary unaudited consolidated management accounts of the Group, which are subject to finalization and, if any, adjustment. It is expected that the audited final results of the Group for 2020/21 will be announced in late September 2021.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Universal Health International Group Holding Limited**  
**Jin Dongtao**  
*Chairman*

Hong Kong, 15 September 2021

*As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Zhao Zehua and Mr. Chu Chuanfu and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.*

\* *For illustrative purpose of this announcement, conversion of RMB into HK\$ is based on the exchange rate of RMB1.00 = HK\$1.20181 (published by The People’s Bank of China on 30 June 2021).*